Rabbit Polyclonal CLDN8 Antibody

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P11182(AMH Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P11182(AMH Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The CLDN8 antibody is a research tool targeting claudin-8 (CLDN8), a member of the claudin family of transmembrane proteins critical for forming tight junctions in epithelial and endothelial cells. Tight junctions regulate paracellular permeability, maintaining cell polarity and barrier integrity. CLDN8. encoded by the *CLDN8* gene, is primarily expressed in tissues such as the gastrointestinal tract, kidneys, and lungs, where it contributes to ion selectivity and epithelial barrier function. Its dysregulation has been linked to pathologies, including inflammatory bowel disease (IBD), renal disorders, and cancers.

In cancer research, CLDN8 expression varies by tissue type and tumor stage. For instance, it is downregulated in colorectal and gastric cancers, correlating with poor prognosis and metastasis, but upregulated in certain ovarian and breast cancers, suggesting context-dependent roles. CLDN8 antibodies are widely used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to study its localization, expression patterns, and interactions with other tight junction proteins.

Recent studies also explore CLDN8 as a therapeutic target. In IBD models, modulating CLDN8 expression could restore barrier function, while in cancer, its suppression or over_expression (depending on context) might influence tumor progression. However, challenges remain in understanding its precise mechanistic roles. CLDN8 antibodies thus serve as vital tools for both basic research and translational studies, bridging gaps between molecular biology and clinical applications.